Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $651000.0.

  • BioLineRx's Net Cash Flow rose 17500.0% to $651000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 24266.79%. This contributed to the annual value of $6.2 million for FY2024, which is 20083.5% up from last year.
  • Per BioLineRx's latest filing, its Net Cash Flow stood at $651000.0 for Q3 2025, which was up 17500.0% from -$2.3 million recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's Net Cash Flow peaked at $3.9 million during Q2 2024, and registered a low of -$3.7 million during Q4 2023.
  • Over the past 3 years, BioLineRx's median Net Cash Flow value was -$868000.0 (recorded in 2024), while the average stood at -$263181.8.
  • Per our database at Business Quant, BioLineRx's Net Cash Flow skyrocketed by 21834.15% in 2024 and then tumbled by 17826.6% in 2025.
  • BioLineRx's Net Cash Flow (Quarter) stood at -$3.7 million in 2023, then skyrocketed by 139.25% to $1.4 million in 2024, then tumbled by 54.73% to $651000.0 in 2025.
  • Its Net Cash Flow stands at $651000.0 for Q3 2025, versus -$2.3 million for Q2 2025 and -$1.3 million for Q1 2025.